Ocular therapeutix™ reports second quarter 2024 results

Sol-r axpaxli™ repeat dosing study in wet amd acceptable to fda as registrational trial enrollment in sol-1 continues to accelerate and sol-r actively enrolling patients cash balance of $459.7m as of june 30, 2024, expected to fund operations into 2028 ocular will host a q2 2024 conference call and webcast today, august 7th, at 8:00 am et bedford, mass., aug. 07, 2024 (globe newswire) -- ocular therapeutix, inc. (nasdaq: ocul, “ocular”, the “company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today reported financial results for the second quarter ended june 30, 2024 and provided recent business highlights, including an update on the phase 3 axpaxli™ (axitinib intravitreal implant, also known as otx-tki) wet age-related macular degeneration (wet amd) program.
SOL Ratings Summary
SOL Quant Ranking